DOCSLIB.ORG

Cardioactive Agents : Metoprolol, Sotalol and Milrinone. Influence of Myocardial Content and Systolic Interval

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

3Õ' î'qt ACUTE HAEMODYNAMIC EFFECTS OF THREE CARDIOACTIVE AGENTS : METOPROLOL, SOTALOL AND MILRINONE. INFLUENCE OF MYOCARDIAL CONTENT AND SYSTOLIC INTERVAL. by Rebecca Helen Ritchie, B.Sc (Hons) A thesis submitted for the degree of Doctor of Philosophy ln The University of Adelaide (Faculty of Medicine) February 1994 Department of Medicine (Cardiology Unit, The Queen Elizabeth Hospital) The University of Adelaide Adelaide, SA, 5000. ll ¡ r -tL',. r,0';(', /1L.)/'t :.: 1 TABLE OF CONTENTS Table of contents 1 Declaration vtl Acknowledgements v111 Publications and communications to learned societies in support of thesis D( Summary xl Chapter 1: General Introduction 1 1.1 Overview 2 1.2 Acute effeots of cardioactive drugs 3 1.2.1 Drug effects 4 l.2.2Determnants of drug effects 5 1.3 Myocardial drug gPtake of cardioactive agents 8 1.3.1 Methods of assessment in humans invívo 9 1.3.2 Results of previous studies 10 1.4Influence of cardioactive drugs on contractile state 11 1.4. 1 Conventional indices 11 I.4.2 The staircase phenomenon t2 1.4.3 The mechanical restitution curve t2 1.5 The present study t4 1.5.1 Current relevant knowledge of the acute haemodynamic effects of the cardioactive drugs under investigation r4 1.5.1.1 Metoprolol 15 1.5.1.2 Sotalol 28 1.5.1.3 Milrinone 43 1.5.2 Cunent relevant knowledge of the short-term pharmacokinetics of the cardioactive drugs under investigation 59 1.5.2.1Metoprolol 59 1.5.2.2 Sotalol 7I ll 1.5.2.3 Milrinone 78 1.5.3 Current relevant knowledge of the potential for rate-dependence of the effects of these cardioactive drugs on contractile state 82 1.5.3.1 MetoProlol 82 1.5.3.2 Sotalol 82 1.5.3.3 Milrinone 83 1.6 Objectives of the curent investigation 84 Chapter 2: Materials and Methods 86 2.1 Methods utilized for invivo (human) and invitro (animat) experimentation 87 2.1.1 Protocol for cardiac catheterization for determination of myocardial drug uptake and measurement of acute effects in humans 87 2.l.ZProtocol for isolated perfused rat hearts 90 2.2 Analyfical methods 92 2.2.1IfPLC quantitation of metoprolol in human whole blood and rat heart homogenates 92 z.z.2LfPLcquantitation of sotalol enantiomers in human whole blood 97 2.2.3L+Lccluantitation of milrinone in human whole btood 103 2.2.3.1Analysis of milrinone in biological samples - results of previous investigations 103 2.2.3.2 Methodology developed for analysis of milrinone in human whole blood samples in the current investigation 104 2.2.41-owry protein assay in rat heart homogenates 109 2.2.5 RIA determination of cAMP concentrations in human plasma 111 2.3 Quantitation of haemodynamic, electrocardiographic and electrophysiologic effects Il4 2.4 Calculation of myocardial drug uptaks ll4 2.5 Correlation between myocardiat drug content and simultaneous effects 117 2.6 Pharmacokinetic and pharmacodynamic models utilized for examining the relationship between myocardial drug content and effect l2O 2.7 Statistical analyses utilized in this thesis 123 lll Chapter 3: Determination of rate-related inotropic effects in humans 128 3.1 Mechanical restitution curve construction 129 3.2 Development of a quantitafive model for the mechanical restitution curve 131 3.2.L Background t3l 3.2.2 Methods 131 3.2.3 Results 132 3.2.3.1Theoretical considerations I32 3.2.3.2 The present investigation 136 3.2.4 Discussion 142 3.3 Other methods of examining the potential for rate-dependence of drug effects on contractile state 149 Chapter 4: Acute myocardial metoprolol uptake : correlation with acute effects and influence of hypoxia 152 4.1 Background and Aims 153 4.2 Methods r54 4.3 Results 155 4.3. 1 Patient characteristics 155 4.3.2 Acute haemodynamic effecs of metoprolol in humans r57 4.3.3 Acute electrocardiographic effects of metoprolol in humans 158 4.3.4 Validity of utilizing femoral arterial metoprolol concentrations as a swrogate for those in the aorta 165 4.3.5 Acute myocardial metoprolol uptake in huma¡rs 165 4.3.6 Acute myocardial metoprolol uptake by isolated Langendorff- perfused rat hearts : influence of hypoxia 1ó8 4.3.7 Conelation between myocardial metoprolol content and acute effects in humans 168 4.3.8 Pharmacokinetic - pharmacodynamic link models between myocardial metoprolol content and effect in humans 174 lv 4.3.9 Metoprolol redistribution into other vascula¡ beds in humans 174 4.3.10 Formation of active metoprolol metabolites in humans 179 4.3.I1Concenffation of metoprolol by red blood cells in humans I79 4.3.12 Serial mechanical restitution curye construction in humans 179 4.3.13 Post-extrasystolic potentiation without a compensatory pause in humans 193 4.3.L4 Application of the curve-fitting model to mechanical restitution curves obtained post-metoprolol administration in humans 183 4.3.15 Examination of hysteresis between myocardial metoprolol content and the rate-dependence index following metoprolol administration in humans 196 4.3.16 Rapid atrial pacing before and after metoprolol injection 191 4.3.L7 Summary of results I93 4.4 Discussion 194 Chapter 5: Acute myocardial uptake of d- and l-sotalol: correlation with acute effects in humans 201 5.1 Background and Aims 202 5.2 Methods 203 5'3 Results 204 5.3.1 Patient cha¡acteristics 204 5.3.2 Acute haemodynamic effects of sotalol 206 5.3.3 Acute electrocardiographic effects of sotalol 206 5.3.4 Acute electrophysiologic effects of sotalol 214 5.3.5 Validity of utilizing femoral arte¡ial sotalol concentrations as a surrogate for those in the aorta 214 5.3.6 Acute myocardial sotalol uptake 214 5.3.7 Correlation between myocardial sotalol content and acute effects 222 5.3.8 Pharmacokinetic - pharmacodynamic link models between myocardial sotalol content and effect 226 5.3.9 Sotalol redistribution into other vascular beds 226 5.3.10 Serial mechanical restitution curve construction 231 v 5.3.11 Post-extrasystolic potentiation without a compensatory pause 234 5.3.12 Application of the curve-frtting model to mechanical restitution curyes obtained post-sotalol injection 237 5.3.L3 Rapid atrial pacing before and after sotalol injection 237 5.3.L4 Submaximal coronary vasodilator reserve 24t 5.3.15 Summary of results 242 5.4 Discussion 243 Chapter 6: Acute myocardial uptake of milrinone : correlation with acute effects and a biochemical marker in humans 249 6.1 Background and Aims 25O 6.2 Methods 251 6.3 Results , 252 6.3.1 Patient characteristics 252 6.3.2 Acute haemodynamic effects of milrinone 252 6.3.3 Acute electrocardiographic effects of milrinone 257 6.3.4 Acute electrophysiologic effects of milrinone 257 6.3.5 Influence of milrinone on plasma cAMP concentrations 257 6.3.6 Validity of utilization of femoral arterial milrinone concentrations as a surogate for those in ttre aorta 266 6.3.7 Acute myocardial milrinone uptake 266 6.3.8 Correlation benveen myocardial milrinone content and acute effects 268 6.3.9 Milrinone redistribution into other vascular beds 273 6.3.10 Serial mechanical restitution curve construction 273 6.3.11 Post-extrasystolic potentiation without a compensatory pause 216 6.3.I2Post-extrasystolic potentiation with a compensatory pause 276 6.3.13 Application of the curve-fitting model to mechanical restitution curyes obtained post-milrinone injection 279 6.3.14 Examination of hysteresis between myocardial milrinone content and the rate dependence index 279 6.3.15 Influence of rapid atrial pacing on LV+dP/dt before and after milrinone injection 283 vl 6.3.16 Submaximal coronary vasodilator reserve 285 6.3.L7 Summary of results 286 6.4 Discussion 287 Chapter 7: General Discussion 294 7.lOverview 295 7.2 Acute effects of cardioactive drugs 296 7.3 Determinants of drug effects : influence of myocardial drug conteht in the present investigation 297 7.4 Myocardial drug uptake of cardioactive agents : comparison with previous studies 2gg 7.5 Influence. of ca¡dioactive drugs on contractile state : modulation by changes in cycle length 301 7.6 Conctusions 304 Bibliography s06 vll DECLARATION This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by any other person, except where due reference has been made in the text. I give consent to this copy,of my thesis, when deposited in the University Library, being available for loan and photocopytng. ret.?.qtt- Signed Date vlll ACKNOWLEDGEMENTS I would like to thank my supervisor Prof John Horowitz for his supervision and guidance. My sincere thanks also to Prof Ivan de la Lande for his advice, encouragement, critical evaluation of the work, and especially his practical assistance with the Langendorff isolated rat heart preparation. The assistance of Dr Dennis Morgan (Victorian College of Pharmacy) and Prof Richard Jarrett (Department of Statistics) was also appreciated, in the pharmacokinetic / pharmacodynamic modelling, and the development of a model for the mechanical restitution curve, respectively. I also wish to thank Dr Yi Zhang for her assistance with data collation for postextrasystolic potentiation, Dr John Hii for his assistance with measurement of the electrophysiologic patameters, and the staff of the Cardiology Research and Cardiac Catheterization Laboratories, and the Department of Clinical Pharmacology for their valuable assistance in the research protocol. My thanks also to the many patients who took part in the study, without whose voluntary participation this work would not have been possible. Finally, I would like to thank Steven, and my close friends, for their support and encouragement during this time.
Recommended publications
  • Theophylline and Selective PDE Inhibitors As Bronchodilators and Smooth Muscle Relaxants

    Theophylline and Selective PDE Inhibitors As Bronchodilators and Smooth Muscle Relaxants

    Eur Respir J, 1995, 8, 637–642 Copyright ERS Journals Ltd 1995 DOI: 10.1183/09031936.95.08040637 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 SERIES 'THEOPHYLLINE AND PHOSPHODIESTERASE INHIBITORS' Edited by M. Aubier and P.J. Barnes Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants K.F. Rabe, H. Magnussen, G. Dent Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Krankenhaus Grosshansdorf, Zentrum für K.F. Rabe, H. Magnussen, G. Dent. ERS Journals Ltd 1995. Pneumologie und Thoraxchirurgie, LVA ABSTRACT: In addition to its emerging immunomodulatory properties, theophy- Hamburg, Grosshansdorf, Germany. lline is a bronchodilator and also decreases mean pulmonary arterial pressure in vivo. The mechanism of action of this drug remains controversial; adenosine Correspondence: K.F. Rabe Krankenhaus Grosshansdorf antagonism, phosphodiesterase (PDE) inhibition and other actions have been advanced Wöhrendamm 80 to explain its effectiveness in asthma. Cyclic adenosine monophosphate (AMP) and D-22927 Grosshansdorf cyclic guanosine monophosphate (GMP) are involved in the regulation of smooth Germany muscle tone, and the breakdown of these nucleotides is catalysed by multiple PDE isoenzymes. The PDE isoenzymes present in human bronchus and pulmonary artery Keywords: Bronchi have been identified, and the pharmacological actions of inhibitors of these enzy- 3',5'-cyclic-nucleotide phosphodiesterase mes have been investigated. phosphodiesterase inhibitors Human bronchus and pulmonary arteries are relaxed by theophylline and by pulmonary artery selective inhibitors of PDE III, while PDE IV inhibitors also relax precontracted smooth muscle theophylline bronchus and PDE V/I inhibitors relax pulmonary artery. There appears to be some synergy between inhibitors of PDE III and PDE IV in relaxing bronchus, and Received: February 1 1995 a pronounced synergy between PDE III and PDE V inhibitors in relaxing pulmon- Accepted for publication February 1 1995 ary artery.
  • Phosphodiesterase (PDE)

    Phosphodiesterase (PDE)

    Phosphodiesterase (PDE) Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules. www.MedChemExpress.com 1 Phosphodiesterase (PDE) Inhibitors, Activators & Modulators (+)-Medioresinol Di-O-β-D-glucopyranoside (R)-(-)-Rolipram Cat. No.: HY-N8209 ((R)-Rolipram; (-)-Rolipram) Cat. No.: HY-16900A (+)-Medioresinol Di-O-β-D-glucopyranoside is a (R)-(-)-Rolipram is the R-enantiomer of Rolipram. lignan glucoside with strong inhibitory activity Rolipram is a selective inhibitor of of 3', 5'-cyclic monophosphate (cyclic AMP) phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM phosphodiesterase. and 240 nM for PDE4A, PDE4B, and PDE4D, respectively. Purity: >98% Purity: 99.91% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 10 mg, 50 mg (R)-DNMDP (S)-(+)-Rolipram Cat. No.: HY-122751 ((+)-Rolipram; (S)-Rolipram) Cat. No.: HY-B0392 (R)-DNMDP is a potent and selective cancer cell (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, AMP(cAMP)-specific phosphodiesterase (PDE) binds PDE3A directly.
  • Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M

    Adrenoceptors Regulating Cholinergic Activity in the Guinea-Pig Ileum 1978) G.M

    - + ! ,' Br. J. Pharmac. (1978), 64, 293-300. F'(O t.,," e reab- ,ellular PHARMACOLOGICAL CHARACTERIZATION OF THE PRESYNAPTIC _-ADRENOCEPTORS REGULATING CHOLINERGIC ACTIVITY IN THE GUINEA-PIG ILEUM 1978) G.M. Departmentof Pharmacology,Allen and HzmburysResearchLimited, Ware, Hertfordshire,SG12 ODJ I The presynaptic ct-adrenoceptors located on the terminals of the cholinergic nerves of the guinea- pig myenteric plexus have been characterized according to their sensitivities to at-adrenoceptor agonists and antagonists. 2 Electrical stimulation of the cholinergic nerves supplying the longitudinal muscle of the guinea-pig ! ileum caused a twitch response. Clonidine caused a concentration-dependent inhibition of the twitch i response; the maximum inhibition obtained was 80 to 95_o of the twitch response. Oxymetazoline and xylazine were qualitatively similar to clonidine but were about 5 times less potent. Phenylephrine and methoxamine also inhibited the twitch response but were at least 10,000 times less potent than clonidine. 3 The twitch-inhibitory effects of clonidine, oxymetazoline and xylazine, but not those of phenyl- ephrine or methoxamine, were reversed by piperoxan (0.3 to 1.0 lag/ml). 4 Lysergic acid diethylamide (LSD) inhibited the twitch response, but also increased the basal tone of the ileum. Mepyramine prevented the increase in tone but did not affect the inhibitory action of LSD. Piperoxan or phentolamine only partially antagonized the inhibitory effect of LSD. 5 Phentolamine, yohimbine, piperoxan and tolazoline were potent, competitive antagonists of the inhibitory effect of clonidine with pA2 values of 8.51, 7.78, 7.64 and 6.57 respectively. 6 Thymoxamine was a weak antagonist of clonidine; it also antagonized the twitch-inhibitory effect of morphine.
  • Phosphodiesterase Inhibitors: Their Role and Implications

    Phosphodiesterase Inhibitors: Their Role and Implications

    International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.1, No.4, pp 1148-1160, Oct-Dec 2009 PHOSPHODIESTERASE INHIBITORS: THEIR ROLE AND IMPLICATIONS Rumi Ghosh*1, Onkar Sawant 1, Priya Ganpathy1, Shweta Pitre1 and V.J.Kadam1 1Dept. of Pharmacology ,Bharati Vidyapeeth’s College of Pharmacy, University of Mumbai, Sector 8, CBD Belapur, Navi Mumbai -400614, India. *Corres.author: rumi 1968@ hotmail.com ABSTRACT: Phosphodiesterase (PDE) isoenzymes catalyze the inactivation of intracellular mediators of signal transduction such as cAMP and cGMP and thus have pivotal roles in cellular functions. PDE inhibitors such as theophylline have been employed as anti-asthmatics since decades and numerous novel selective PDE inhibitors are currently being investigated for the treatment of diseases such as Alzheimer’s disease, erectile dysfunction and many others. This review attempts to elucidate the pharmacology, applications and recent developments in research on PDE inhibitors as pharmacological agents. Keywords: Phosphodiesterases, Phosphodiesterase inhibitors. INTRODUCTION Alzheimer’s disease, COPD and other aliments. By cAMP and cGMP are intracellular second messengers inhibiting specifically the up-regulated PDE isozyme(s) involved in the transduction of various physiologic with newly synthesized potent and isoezyme selective stimuli and regulation of multiple physiological PDE inhibitors, it may possible to restore normal processes, including vascular resistance, cardiac output, intracellular signaling selectively, providing therapy with visceral motility, immune response (1), inflammation (2), reduced adverse effects (9). neuroplasticity, vision (3), and reproduction (4). Intracellular levels of these cyclic nucleotide second AN OVERVIEW OF THE PHOSPHODIESTERASE messengers are regulated predominantly by the complex SUPER FAMILY superfamily of cyclic nucleotide phosphodiesterase The PDE super family is large, complex and represents (PDE) enzymes.
  • The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
  • Order in Council 1243/1995

    Order in Council 1243/1995

    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
  • NATURE 199 Heart Was Removed with the Great Vessels Cut Close to the Heart, A~D the Organ Weighed

    NATURE 199 Heart Was Removed with the Great Vessels Cut Close to the Heart, A~D the Organ Weighed

    No. 49t5 January 11, 1964 NATURE 199 heart was removed with the great vessels cut close to the heart, a~d the organ weighed. The weights of each OH embryo and 1ts heart are seen tabulated in Fig. l. · CH • The largest embryos were seen at 37·5° C. The heart:; /\ /~_CH. CH2 N( . CH, from the group at 32·5° C were largest, even though the j 'H embryos bearing these hearts were smaller than those at Vv# the normal temperature. On gross examination we saw I that the increase in size at 32·5° C consisted of enlarge­ OH NR2 ment ~f the chambers of the heart as well as thickening IIa ~·~ - N(CH,.)2 of thmr walls. On microscopic section the increased CH . CH2 • N . R 2 heart tissue mass was found to be composed of heart I muscle and supporting tissues, not of an inflammatory exudate or cedoma. Two other gross changes were consistently present. In 00 II the low-temperature groups the intra-abdominal veins of the embryos as well as veins of the extra-embryonic to discover whether pronethalol also could produce local membranes were distended. Also the kidneys were en­ anresthesia. larged-both the mesonephric and metanephric kidneys. Guinea pigs were lightly anresthetized with sodium To seo whether the variation in the size of heart pentobarbitone (30 mgfkg intraperitoneally) and local resulting from the difference in temperature of incubation anresthetic potency determined by the intradermal weal would be observed in heart fragments transplanted to method of Biilbring and Wajda•. It was found that the chorioallantoic membrane, we removed the hearts of pronethalol is 1·8 times as active as procaine (log R = several 8-day-old embryos, pooled them, cut them into 0·270 ± 0·05).
  • Various Subtypes of Phosphodiesterase Inhibitors Differentially Regulate Pulmonary Vein and Sinoatrial Node Electrical Activities

    Various Subtypes of Phosphodiesterase Inhibitors Differentially Regulate Pulmonary Vein and Sinoatrial Node Electrical Activities

    EXPERIMENTAL AND THERAPEUTIC MEDICINE 19: 2773-2782, 2020 Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities YUNG‑KUO LIN1,2*, CHEN‑CHUAN CHENG3*, JEN‑HUNG HUANG1,2, YI-ANN CHEN4, YEN-YU LU5, YAO‑CHANG CHEN6, SHIH‑ANN CHEN7 and YI-JEN CHEN1,8 1Department of Internal Medicine, Division of Cardiovascular Medicine, Wan Fang Hospital; 2Department of Internal Medicine, Division of Cardiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11696; 3Division of Cardiology, Chi‑Mei Medical Center, Tainan 71004; 4Division of Nephrology; 5Division of Cardiology, Department of Internal Medicine, Sijhih Cathay General Hospital, New Taipei 22174; 6Department of Biomedical Engineering, National Defense Medical Center, Taipei 11490; 7Heart Rhythm Center and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217; 8Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11696, Taiwan, R.O.C. Received May 16, 2019; Accepted January 9, 2020 DOI: 10.3892/etm.2020.8495 Abstract. Phosphodiesterase (PDE)3-5 are expressed in 20.7±4.6%, respectively. In addition, milrinone (1 and 10 µM) cardiac tissue and play critical roles in the pathogenesis of induced the occurrence of triggered activity (0/8 vs. 5/8; heart failure and atrial fibrillation. PDE inhibitors are widely P<0.005) in PVs. Rolipram increased PV spontaneous activity used in the clinic, but their effects on the electrical activity by 7.5±1.3‑9.5±4.0%, although this was not significant, and did of the heart are not well understood. The aim of the present not alter SAN spontaneous activity.
  • Toxic, and Comatose-Fatal Blood-Plasma Concentrations (Mg/L) in Man

    Toxic, and Comatose-Fatal Blood-Plasma Concentrations (Mg/L) in Man

    Therapeutic (“normal”), toxic, and comatose-fatal blood-plasma concentrations (mg/L) in man Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Abacavir (ABC) 0.9-3.9308 appr. 1.5 [1,2] Acamprosate appr. 0.25-0.7231 1311 13-20232 [3], [4], [5] Acebutolol1 0.2-2 (0.5-1.26)1 15-20 3-11 [6], [7], [8] Acecainide see (N-Acetyl-) Procainamide Acecarbromal(um) 10-20 (sum) 25-30 Acemetacin see Indomet(h)acin Acenocoumarol 0.03-0.1197 0.1-0.15 3-11 [9], [3], [10], [11] Acetaldehyde 0-30 100-125 [10], [11] Acetaminophen see Paracetamol Acetazolamide (4-) 10-20267 25-30 2-6 (-13) [3], [12], [13], [14], [11] Acetohexamide 20-70 500 1.3 [15] Acetone (2-) 5-20 100-400; 20008 550 (6-)8-31 [11], [16], [17] Acetonitrile 0.77 32 [11] Acetyldigoxin 0.0005-0.00083 0.0025-0.003 0.005 40-70 [18], [19], [20], [21], [22], [23], [24], [25], [26], [27] 1 Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Acetylsalicylic acid (ASS, ASA) 20-2002 300-3502 (400-) 5002 3-202; 37 [28], [29], [30], [31], [32], [33], [34] Acitretin appr. 0.01-0.05112 2-46 [35], [36] Acrivastine -0.07 1-2 [8] Acyclovir 0.4-1.5203 2-583 [37], [3], [38], [39], [10] Adalimumab (TNF-antibody) appr. 5-9 146 [40] Adipiodone(-meglumine) 850-1200 0.5 [41] Äthanol see Ethanol -139 Agomelatine 0.007-0.3310 0.6311 1-2 [4] Ajmaline (0.1-) 0.53-2.21 (?) 5.58 1.3-1.6, 5-6 [3], [42] Albendazole 0.5-1.592 8-992 [43], [44], [45], [46] Albuterol see Salbutamol Alcuronium 0.3-3353 3.3±1.3 [47] Aldrin -0.0015 0.0035 50-1676 (as dieldrin) [11], [48] Alendronate (Alendronic acid) < 0.005322 -6 [49], [50], [51] Alfentanil 0.03-0.64 0.6-2.396 [52], [53], [54], [55] Alfuzosine 0.003-0.06 3-9 [8] 2 Substance Blood-plasma concentration (mg/L) t½ (h) Ref.
  • Drug Schedules Regulation B.C

    Drug Schedules Regulation B.C

    Pharmacy Operations and Drug Scheduling Act DRUG SCHEDULES REGULATION B.C. Reg. 9/98 Deposited and effective January 9, 1998 Last amended June 28, 2018 by B.C. Reg. 137/2018 Consolidated Regulations of British Columbia This is an unofficial consolidation. Point in time from June 28 to December 6, 2018 B.C. Reg. 9/98 (O.C. 35/98), deposited and effective January 9, 1998, is made under the Pharmacy Operations and Drug Scheduling Act, S.B.C. 2003, c. 77, s. 22. This is an unofficial consolidation provided for convenience only. This is not a copy prepared for the purposes of the Evidence Act. This consolidation includes any amendments deposited and in force as of the currency date at the bottom of each page. See the end of this regulation for any amendments deposited but not in force as of the currency date. Any amendments deposited after the currency date are listed in the B.C. Regulations Bulletins. All amendments to this regulation are listed in the Index of B.C. Regulations. Regulations Bulletins and the Index are available online at www.bclaws.ca. See the User Guide for more information about the Consolidated Regulations of British Columbia. The User Guide and the Consolidated Regulations of British Columbia are available online at www.bclaws.ca. Prepared by: Office of Legislative Counsel Ministry of Attorney General Victoria, B.C. Point in time from June 28 to December 6, 2018 Pharmacy Operations and Drug Scheduling Act DRUG SCHEDULES REGULATION B.C. Reg. 9/98 Contents 1 Alphabetical order 2 Sale of drugs 3 [Repealed] SCHEDULES Alphabetical order 1 (1) The drug schedules are printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
  • PDE4 and PDE5 Regulate Cyclic Nucleotide Contents and Relaxing Effects on Carbachol-Induced Contraction in the Bovine Abomasum

    PDE4 and PDE5 Regulate Cyclic Nucleotide Contents and Relaxing Effects on Carbachol-Induced Contraction in the Bovine Abomasum

    Advance Publication The Journal of Veterinary Medical Science Accepted Date: 16 Sep 2014 J-STAGE Advance Published Date: 15 Oct 2014 FULL PAPER Pharmacology PDE4 and PDE5 regulate Cyclic Nucleotide Contents and Relaxing Effects on Carbachol-induced Contraction in the Bovine Abomasum Takeharu KANEDA1)*, Yuuki KIDO1), 2), Tsuyoshi TAJIMA1), Norimoto URAKAWA1) and Kazumasa SHIMIZU1) 1)Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, and 2)School of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University, 7-1 Kyonan-cho 1-chome, Musashino, Tokyo 180-8602, Japan *Correspondence to: Takeharu KANEDA, Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Nippon Veterinary and Life Science University, 7-1 Kyonan-cho 1-chome, Musashino, Tokyo 180-8602, Japan Tel. +81-422-31-4457 Fax +81-422-31-4457 E-mail [email protected] Running head: PDE4 and PDE5 in the Bovine Abomasum ABSTRACT. The effects of various selective phosphodiesterase（PDE）inhibitors on carbachol (CCh)-induced contraction in the bovine abomasum were investigated. Various selective PDE inhibitors, vinpocetine (type 1), erythro-9-(2- hydroxy-3-nonyl)adenine (EHNA, type 2), milrinone (type 3), Ro20-1724 (type 4), vardenafil (type 5), BRL-50481 (type 7) and BAY73-6691 (type 9), inhibited CCh-induced contractions in a concentration-dependent manner. Among the PDE inhibitors, Ro20-1724 and vardenafil induced more relaxation than the other inhibitors based on the data for the IC50 or maximum relaxation. In smooth muscle of the bovine abomasum, we showed the expression of PDE4B, 4C, 4D and 5 by RT-PCR analysis. In the presence of CCh, Ro20-1724 increased the cAMP content, but not the cGMP content.
  • ACMD Advisory Council on the Misuse of Drugs

    ACMD Advisory Council on the Misuse of Drugs

    ACMD Advisory Council on the Misuse of Drugs Consideration of the naphthylpyrovalerone analogues and related compounds. 1 ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Will Reynolds 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0454 [email protected] Rt Hon Theresa May MP 2 Marsham Street London SW1P 4DF 7th July 2010 Dear Home Secretary, The ACMD indicated in its advice of 31st March 2010 on the cathinones that it would provide you with further advice on the naphthyl analogues of pyrovalerone (including naphyrone) and other such analogues. I have pleasure in attaching the Advisory Council on the Misuse of Drugs report on the ‘Consideration of the naphthylpyrovalerone analogues and related compounds’. The ACMD recognise the significant public health issue that ‘legal highs’ present. Our report references recent work on test purchases of a number of ‘legal highs’ that demonstrate their many and varied compositions. In this report the evidence highlights the dangers of purchasing compounds which are likely to contain harmful compounds and very often will not be the same as the material advertised and may be more harmful and illegal. Users of ‘legal highs’ should be acutely aware that just because it is being advertised as legal does not make a substance safe, nor may it be legal. Along with mephedrone and related compounds, the public health response should focus on the discrepancy between the compounds that are purported to be contained in the ‘legal high’ for sale and what the customer actually gets.